Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Depreciation and Depletion (2019 - 2025)

AVITA Medical's Depreciation and Depletion history spans 7 years, with the latest figure at $400000.0 for Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 17.99% year-over-year to $400000.0; the TTM value through Dec 2025 reached $1.6 million, up 60.6%, while the annual FY2025 figure was $1.6 million, 60.0% up from the prior year.
  • Depreciation and Depletion reached $400000.0 in Q4 2025 per RCEL's latest filing, down from $421000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $421000.0 in Q3 2025 to a low of $122000.0 in Q4 2022.
  • Average Depreciation and Depletion over 5 years is $218000.0, with a median of $156000.0 recorded in 2023.
  • Peak YoY movement for Depreciation and Depletion: dropped 21.81% in 2021, then surged 113.9% in 2025.
  • A 5-year view of Depreciation and Depletion shows it stood at $147000.0 in 2021, then fell by 17.01% to $122000.0 in 2022, then surged by 45.9% to $178000.0 in 2023, then surged by 90.45% to $339000.0 in 2024, then grew by 17.99% to $400000.0 in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Depreciation and Depletion are $400000.0 (Q4 2025), $421000.0 (Q3 2025), and $400000.0 (Q2 2025).